Literature DB >> 4536911

Elective splenorenal anastomosis.

A G Riddell, K Bloor, K E Hobbs, N Jacquet.   

Abstract

Thirty-six patients underwent splenorenal anastomosis for haemorrhage from oesophageal varices. Twenty-nine patients were cirrhotics and seven had extrahepatic blocks or congenital hepatic fibrosis. The patients have been followed from 16 years to 6 months. The operative mortality was 11%. Recurrent haemorrhage occurred in two patients (6%) and neurological manifestations in 38% of the patients at risk. It is concluded that splenorenal anastomosis is associated with a high degree of shunt patency.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4536911      PMCID: PMC1787630          DOI: 10.1136/bmj.1.5802.731

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  3 in total

1.  Critical comparative analysis of early and late results of splenorenal and direct portacaval shunts performed in 169 patients with portal cirrhosis.

Authors:  R R LINTON; D S ELLIS; J E GEARY
Journal:  Ann Surg       Date:  1961-09       Impact factor: 12.969

2.  Elective portasystemic shunts: morbidity and survival data.

Authors:  B A Barnes; F W Ackroyd; G E Battit; P A Kantrowitz; R H Schapiro; W E Strole; D P Todd; W V McDermott
Journal:  Ann Surg       Date:  1971-07       Impact factor: 12.969

Review 3.  The present status of shunts for portal hypertension in cirrhosis.

Authors:  N D Grace; H Muench; T C Chalmers
Journal:  Gastroenterology       Date:  1966-05       Impact factor: 22.682

  3 in total
  3 in total

Review 1.  Portal hypertension--25 years of progress.

Authors:  B R MacDougall; D Westaby; L A Blendis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Primary biliary cirrhosis, presenting as gastrointestinal haemorrhage.

Authors:  A M Dawson; M A Birnstingl; J A Gibson
Journal:  Proc R Soc Med       Date:  1973-09

3.  Risks in therapeutic portacaval and splenorenal shunts.

Authors:  R A Malt; J Szczerban; R B Malt
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.